This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Scroll down

1.

Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. doi:10.1093/eurheartj/ehz486.


2.

American Diabetes Association. 11. Chronic kidney disease and risk management: standards of medical care in diabetes—2023. Diabetes Care. 2023;46(Suppl. 1):S191–S202. doi:10.2337/dc23-s011.


3.

Skolnic N, Style AJ. Importance of early screening and diagnosis of chronic kidney disease in patients with type 2 diabetes. Diabetes Ther. 2021;12:1613–1630. doi:10.1007/s13300-021-01050-w.


4.

Schneider MP, Virgitti JB, Peach E, et al. REVEAL-CKD: undiagnosed chronic kidney disease in patients with type 2 diabetes in Germany and France. Diabetes. 2022;71(Supplement_1):1213-P. doi:10.2337/db22-1213-P.


5.

Hirst JA, Ordóñez Mena JM, O’Callaghan CA, et al. Prevalence and factors associated with multimorbidity among primary care patients with decreased renal function. PLoS ONE. 2021;16(1):e0245131. doi:10.1371/journal.pone.0245131.

6.

Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015;1:15018. doi:10.1038/nrdp.2015.18.

7.

Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302–308. doi:10.1681/ASN.2012070718.

8.

Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol. 2018;17(1):83. doi:10.1186/s12933-018-0728-6.

9.

Jankowski J, Floege J, Fliser D, et al. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143:1157–1172. doi:10.1161/CIRCULATIONAHA.120.050686.

10.

de Boer IH, Rue TS, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305:2532–2539. doi:10.1001/jama.2011.861.

11.

Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98:S1–S115. doi:10.1016/j.kint.2020.06.019.

12.

Bramlage P, Lanzinger S, Hess E, et al. Renal function deterioration in adult patients with type-2 diabetes. BMC Nephrology. 2020;21(1):312. doi:10.1186/s12882-020-01952-0.

13.

Go AS, Yang J, Tan TC, et al. Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus. BMC Nephrology. 2018;19:146. doi:10.1186/s12882-018-0942-21.

14.

Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295‒2306. doi:10.1056/NEJMoa1811744.

15.

Bakris G, Agarwal R, Anker SD, et al. Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219‒2229. doi:10.1056/NEJMoa2025845.

16.

Heerspink H, Stefánsson BV, Correa‑Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436‒1446. doi:10.1056/NEJMoa2024816.

17.

EMPA-KIDNEY Collaborative Group. Design, recruitment and baseline characteristics of the EMPA-KIDNEY trial. Nephrol Dial Transplant. 2022;37:1317‒1329. doi:10.1093/ndt/gfac040.

18.

Gaede P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59:2298–2307. doi:10.1007/s00125-016-4065-6.

19.

Ueki K, Sasako T, Okazaki Y, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:951–964. doi:10.1016/S2213-8587(17)30327-3.

20.

Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(Suppl 5S):S1–S127. doi:10.1016/j.kint.2022.06.008.

21.

Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–2786. doi:10.2337/dci22-0034.